APA (7th ed.) Citation

Liu, J., Burris, H., Wang, J. S., Barroilhet, L., Gutierrez, M., Wang, Y., . . . Moore, K. (2021). An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer. Gynecologic Oncology, 163(3), 473. https://doi.org/10.1016/j.ygyno.2021.09.023

Chicago Style (17th ed.) Citation

Liu, Joyce, et al. "An Open-label Phase I Dose-escalation Study of the Safety and Pharmacokinetics of DMUC4064A in Patients with Platinum-resistant Ovarian Cancer." Gynecologic Oncology 163, no. 3 (2021): 473. https://doi.org/10.1016/j.ygyno.2021.09.023.

MLA (9th ed.) Citation

Liu, Joyce, et al. "An Open-label Phase I Dose-escalation Study of the Safety and Pharmacokinetics of DMUC4064A in Patients with Platinum-resistant Ovarian Cancer." Gynecologic Oncology, vol. 163, no. 3, 2021, p. 473, https://doi.org/10.1016/j.ygyno.2021.09.023.